secwatch.observer — SEC 8-K summary
======================================

Issuer:     BURZYNSKI RESEARCH INSTITUTE INC (BZYR)
CIK:        0000724445
Form:       8-K
Filed at:   2023-05-22T23:59:59+00:00
Accession:  0001104659-23-063151
Event type: other_material
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BZYR licenses antineoplaston patents from CEO; research funding secured through Feb 2024
--------------------------------------------------------------------------------

- License from Dr. Burzynski for exclusive rights to four US patents and pending applications for antineoplastons in US/Canada.
- Research Funding Agreement: Dr. Burzynski funds all basic research and FDA-related trial costs; term to Feb 2024, auto-renewable.
- Amended Royalty and Research Funding Agreements limited to US/Canada scope.
- License can terminate if Burzynski removed as officer/director or if another party equals his voting power.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/724445/000110465923063151/0001104659-23-063151-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/724445/000110465923063151/tm2316366d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-063151

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer